Total Payments
$14,607
2024 Payments
$76.28
Companies
9
Transactions
17
Medicare Patients
769
Medicare Billing
$133,385
Payment Breakdown by Category
Consulting$8,733 (59.8%)
Research$4,697 (32.2%)
Other$990.00 (6.8%)
Food & Beverage$187.61 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,733 | 5 | 59.8% |
| Unspecified | $4,697 | 1 | 32.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $990.00 | 1 | 6.8% |
| Food and Beverage | $187.61 | 10 | 1.3% |
Payments by Type
General
$9,911
16 transactions
Research
$4,697
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $4,697 | 1 | $0 (2020) |
| HRA PHARMA RARE DISEASES | $3,500 | 2 | $0 (2021) |
| GENZYME CORPORATION | $2,833 | 1 | $0 (2017) |
| Bayer HealthCare Pharmaceuticals Inc. | $2,400 | 2 | $0 (2020) |
| Exelixis Inc. | $990.00 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $129.83 | 7 | $0 (2024) |
| EMD Serono, Inc. | $19.82 | 1 | $0 (2022) |
| BeiGene USA, Inc. | $19.15 | 1 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $18.81 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $76.28 | 4 | AstraZeneca Pharmaceuticals LP ($57.13) |
| 2023 | $72.70 | 4 | AstraZeneca Pharmaceuticals LP ($72.70) |
| 2022 | $19.82 | 1 | EMD Serono, Inc. ($19.82) |
| 2021 | $3,009 | 3 | HRA PHARMA RARE DISEASES ($2,000) |
| 2020 | $7,697 | 3 | F. Hoffmann-La Roche AG ($4,697) |
| 2019 | $900.00 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($900.00) |
| 2017 | $2,833 | 1 | GENZYME CORPORATION ($2,833) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $19.15 | General |
| Category: Oncology | ||||||
| 08/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.80 | General |
| 07/01/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $26.03 | General |
| Category: Oncology | ||||||
| 03/27/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Oncology | ||||||
| 09/16/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $25.14 | General |
| Category: Oncology | ||||||
| 04/27/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Oncology | ||||||
| 04/12/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: Oncology | ||||||
| 01/11/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Oncology | ||||||
| 02/24/2022 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.82 | General |
| 12/13/2021 | HRA PHARMA RARE DISEASES | Lysodren (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: adrenal corticolcarcinoma | ||||||
| 12/09/2021 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2021 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $990.00 | General |
| Category: Oncology | ||||||
| 12/02/2020 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 11/18/2020 | HRA Pharma Rare Diseases | Lysodren (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Inoperable adrenal cortical carcinoma | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $4,696.81 | Research |
| Study: A PHASE I, OPEN LABEL, DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB MPDL3280A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR HEMATOLOGIC MALIGNANCIES • Category: BioOncology | ||||||
| 05/23/2019 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Oncology | ||||||
| 01/01/2017 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Consulting Fee | In-kind items and services | $2,833.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE I, OPEN LABEL, DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB MPDL3280A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR HEMATOLOGIC MALIGNANCIES | F. Hoffmann-La Roche AG | $4,697 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 156 | 324 | $126,042 | $27,284 |
| 2022 | 3 | 143 | 307 | $128,784 | $30,308 |
| 2021 | 6 | 216 | 401 | $153,142 | $37,286 |
| 2020 | 6 | 254 | 537 | $194,298 | $38,506 |
Total Patients
769
Total Services
1,569
Medicare Billing
$133,385
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 49 | 135 | $57,915 | $13,465 | 23.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 55 | 85 | $27,030 | $5,871 | 21.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 72 | $21,816 | $4,337 | 19.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 21 | 21 | $12,978 | $2,525 | 19.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $6,303 | $1,087 | 17.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 51 | 178 | $76,362 | $19,191 | 25.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 54 | 91 | $28,938 | $6,048 | 20.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 38 | 38 | $23,484 | $5,069 | 21.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 72 | 202 | $86,658 | $21,807 | 25.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 60 | 87 | $27,666 | $6,154 | 22.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 38 | 38 | $23,484 | $5,123 | 21.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 18 | 38 | $6,422 | $2,095 | 32.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 20 | $5,520 | $1,585 | 28.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 14 | 16 | $3,392 | $521.44 | 15.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 86 | 293 | $115,505 | $22,417 | 19.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 77 | 121 | $35,795 | $6,164 | 17.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 48 | 48 | $26,956 | $5,717 | 21.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 27 | $7,452 | $2,200 | 29.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 13 | 29 | $4,901 | $1,573 | 32.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 18 | 19 | $3,689 | $435.00 | 11.8% |
About Dr. Jill Gilbert, MD
Dr. Jill Gilbert, MD is a Hematology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437186418.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jill Gilbert, MD has received a total of $14,607 in payments from pharmaceutical and medical device companies, with $76.28 received in 2024. These payments were reported across 17 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($8,733).
As a Medicare-enrolled provider, Gilbert has provided services to 769 Medicare beneficiaries, totaling 1,569 services with total Medicare billing of $133,385. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology
- Location Nashville, TN
- Active Since 06/27/2006
- Last Updated 10/10/2024
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1437186418
Products in Payments
- Tecentriq (Biological) $4,697
- Lysodren (Drug) $3,500
- NO PRODUCT DISCUSSED (Drug) $2,833
- Vitrakvi (Drug) $2,400
- CABOMETYX (Drug) $990.00
- LYNPARZA (Drug) $73.59
- IMFINZI (Biological) $40.44
- TEVIMBRA (Drug) $19.15
- LIBTAYO (Biological) $18.81
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Nashville
Dr. Navneet Majhail, Md, MD
Hematology — Payments: $62,360
Hematology $62,360
Dr. Michael Debaun, Md, MD
Hematology — Payments: $39,880
Hematology $39,880
Ben Park, M.d, M.D
Hematology — Payments: $22,841
Hematology $22,841
Wesam Ahmed, Md, MD
Hematology — Payments: $11,770
Hematology $11,770
Dr. Katherine Walsh, M.d, M.D
Hematology — Payments: $7,046
Hematology $7,046
Emily Chan, Md, Phd, MD, PHD
Hematology — Payments: $2,950
Hematology $2,950